SCHEMBL824149

SCHEMBL824149

Nc1cccc(C2CCCCC2)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 4/20 0.46
ALOX5AP P20292 3/20 0.42
PTPN5 P54829 4/20 0.41
PTPN2 P17706 1/20 0.41
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
NUDT1 P36639 1/20 0.39
BACE1 P56817 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38
TDO2 P48775 1/20 0.38
GAA P10253 1/20 0.38
MMP2 P08253 1/20 0.37
HDAC3 O15379 2/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC2 Q92769 2/20 0.37
HDAC4 P56524 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
CEL P19835 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4969688 0.98 FEN1 (0.44) FEN1ALOX5APPTPN5PTPN2KDM4E
SCHEMBL4960398 0.86 PTPN5 (0.46) FEN1ALOX5APPTPN5PTPN2KDM4E
SCHEMBL201425 0.86 PTPN5 (0.46) FEN1ALOX5APPTPN5PTPN2KDM4E
SCHEMBL4958978 0.86 PTPN5 (0.46) FEN1ALOX5APPTPN5PTPN2KDM4E
SCHEMBL4958862 0.86 PTPN5 (0.46) FEN1ALOX5APPTPN5PTPN2KDM4E
SCHEMBL4959318 0.86 PTPN5 (0.46) FEN1ALOX5APPTPN5PTPN2KDM4E
SCHEMBL4960831 0.83 PTPN5 (0.44) FEN1ALOX5APPTPN5PTPN2KDM4E
SCHEMBL824155 0.81 ESR2 (0.43) FEN1ALOX5APMEN1KMT2AGAA
SCHEMBL3793541 0.81 CEL (0.43) FEN1PTPN5PTPN2KDM4EMAPT
SCHEMBL21626185 0.80 PTPN5 (0.52) FEN1ALOX5APPTPN5PTPN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143287-B2 Thrombopoietin mimetics STATEGICS, INC. (US) 2012-03-27 US disclosed
US-8143287-B2 Thrombopoietin mimetics STATEGICS, INC. (US) 2012-03-27 US disclosed
US-20100323965-A1 Thrombopoietin Mimetics STATEGICS, INC. (US) 2010-12-23 US disclosed
US-20100323965-A1 Thrombopoietin Mimetics STATEGICS, INC. (US) 2010-12-23 US disclosed
US-7786159-B2 Thrombopoietin mimetics STATEGICS, INC. (US) 2010-08-31 US disclosed
US-7786159-B2 Thrombopoietin mimetics STATEGICS, INC. (US) 2010-08-31 US disclosed
US-20080139621-A1 Thrombopoietin Mimetics STATEGICS, INC. (US) 2008-06-12 US disclosed
US-20080139621-A1 Thrombopoietin Mimetics STATEGICS, INC. (US) 2008-06-12 US disclosed
WO-2008070583-A2 THROMBOPOIETIN MIMETICS STATEGICS, INC. (US) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139621-A1 Thrombopoietin Mimetics MPL, THPO, TEK FEN1 2696/4885ALOX5AP 707/4885PTPN5 269/4885
US-20100323965-A1 Thrombopoietin Mimetics MPL, THPO, TEK FEN1 2696/4885ALOX5AP 707/4885PTPN5 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.